Managing anxiety in Parkinson's disease: the role of nonpharmacological strategies

Natalia P. Rocha; Antonio L. Teixeira

doi:10.1590/0004-282X20180081

Arquivos de Neuro-Psiquiatria, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(08): 497-498
DOI: 10.1590/0004-282X20180081

Editorial

Managing anxiety in Parkinson's disease: the role of nonpharmacological strategies

Abordagem da ansiedade na doença de Parkinson: papel de estratégias não-farmacológicas

Authors

Natalia P. Rocha

¹Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica, Belo Horizonte MG, Brasil

²The University of Texas Health Science Center at Houston, McGovern Medical School, Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, Houston, Texas, USA
Antonio L. Teixeira

¹Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica, Belo Horizonte MG, Brasil

²The University of Texas Health Science Center at Houston, McGovern Medical School, Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, Houston, Texas, USA

Abstract

Volltext

Referenzen

References
1 Jain S, Goldstein DS. What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy. Neurobiol Dis. 2012 Jun;46(3):505–7. https://doi.org/10.1016/j.nbd.2012.04.013
2 Kummer A, Teixeira AL. Neuropsychiatry of Parkinson's disease. Arq Neuropsiquiatr. 2009 Sep;67(3b 3B):930–9. https://doi.org/10.1590/S0004-282X2009000500033
3 Mele B, Holroyd-Leduc J, Smith EE, Pringsheim T, Ismail Z, Goodarzi Z. Detecting anxiety in individuals with Parkinson disease: A systematic review. Neurology. 2018 Jan;90(1):e39–47. https://doi.org/10.1212/WNL.20180081201800814771
4 Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SR, Grill S et al. Pharmacologic treatment of anxiety disorders in Parkinson disease. Am J Geriatr Psychiatry. 2013 June;21(6):520-8. https://doi.org/10.1016/j.jagp.2012.10.023
5 Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Options Psychiatry. 2017 Mar;4(1):33-46. https://doi.org/10.1007/s40501-017-0102-4
6 Dissanayaka NN, Pye D, Mitchell LK, Byrne GJ, O'Sullivan JD, Marsh R, et al. Cognitive Behavior Therapy for Anxiety in Parkinson's Disease: Outcomes for Patients and Caregivers. Clin Gerontol. 2017 May-Jun;40(3):159–71. https://doi.org/10.1080/07317115.2016.1240131
7 Ferreira RM, Alves WM, Lima TA, Alves TG, Alves Filho PA, Pimentel CP, et al. The effect of resistance training on the anxiety symptoms and quality of life in elderly people with Parkinson's disease: randomized controlled trial. Arq Neuropsiquiatr. 2018;76(8):499-506. https://doi.org/10.1590/0004-282X20180071
8 Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013 Mar;28(3):311-8. https://doi.org/10.1002/mds.25292